Get the Stockscreener App
78.53
0.39%
0.275
Edwards Lifesciences Corp stock is traded at $78.53, with a volume of 2.67M.
It is up +0.39% in the last 24 hours and up +2.71% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$78.26
Open:
$78.12
24h Volume:
2.67M
Relative Volume:
0.63
Market Cap:
$46.11B
Revenue:
$5.69B
Net Income/Loss:
$1.41B
P/E Ratio:
11.30
EPS:
6.95
Net Cash Flow:
$577.90M
1W Performance:
+0.52%
1M Performance:
+2.71%
6M Performance:
+3.83%
1Y Performance:
+13.99%
1-Day Range:
$77.65
$78.94
1-Week Range:
$76.07
$78.94
52-Week Range:
$64.00
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
78.53 | 45.95B | 5.69B | 1.41B | 577.90M | 6.95 |
|
ABT
Abbott Laboratories
|
130.43 | 229.31B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 152.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.52 | 146.01B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.94 | 119.18B | 33.54B | 4.69B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
FTC Sues to Block Edwards LifeSciences Medical Device Deal - MSN
Edwards Lifesciences’ TRISCEND II Trial: A Game-Changer in Tricuspid Valve Treatment? - MSN
Stock Analysis | Edwards Lifesciences OutlookNavigating Mixed Signals in a Volatile Landscape - AInvest
Edwards Lifesciences Hits $0.2B Trade Volume Amid Trial Progress Ranks 479th in Daily Activity - AInvest
Edwards Lifesciences’ ENCIRCLE Trial: A New Hope for Mitral Regurgitation Patients - TipRanks
Edwards Lifesciences’ TRISCEND Study: A Game-Changer in Tricuspid Valve Replacement? - TipRanks
FTC Moves to Block Edwards Lifesciences’ $945 Million Acquisition of JenaValve Over Competition Concerns - MSN
FTC to block Edwards Lifesciences’ acquisition of JenaValve due to competitive concerns - Yahoo Finance
Edwards Lifesciences Rebounds on Institutional Buys Despite Securities Probe as $220M Volume Ranks Among Top 500 - AInvest
Edwards Lifesciences Advances with SAPIEN X4 Heart Valve Study - TipRanks
EDWARDS (EW) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Edwards Lifesciences Rises 0.97% Amid 427th-Ranked Trading Volume as Fundamentals and Technicals Clash - AInvest
Moody’s revises Edwards Lifesciences outlook to positive, affirms Baa2 - Investing.com
Moody’s revises Edwards Lifesciences outlook to positive, affirms Baa2 By Investing.com - Investing.com Canada
Edwards Lifesciences Stock: Analyst Estimates & Ratings - Barchart.com
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards Lifesciences Ranks 458th in Trading Volume as Institutional Splits and High-Return Strategy Highlight Volatile Market Dynamics - AInvest
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve - MSN
FTC Sounds Alarm On Edwards' Attempt To Corner Heart Device Market - Benzinga
Edwards Lifesciences Leads Heart Device Market With Value Upside - Finimize
Edwards Lifesciences’ ALT-FLOW II Trial: A Key Update for Heart Failure Treatment - TipRanks
Baird Adjusts Price Target on Edwards Lifesciences to $81 From $79, Maintains Neutral Rating - MarketScreener
FTC moves to block Edwards’ acquisition of JenaValve Technology - Medical Buyer
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve - WKZO
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
FTC sues to block Edwards Lifesciences purchase of JenaValve - MSN
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve | Business Information & News | FE - Westlaw Today
Bank Groups Urge Congress to Close ‘Loopholes’ in GENIUS Act - PYMNTS.com
FTC Files Lawsuit to Block Edwards Lifesciences’ Purchase of JenaValve Technology - The Wall Street Journal
Edwards Lifesciences' deal with JenaValve would limit device access, US FTC says - MLex
FTC moves to block Edwards Lifesciences’ JenaValve acquisition - MassDevice
JenaValve Responds to FTC’s Action Against Proposed Edwards Lifesciences Acquisition - The Manila Times
Jenavalve disagrees with FTC's decision against proposed Edwards Lifesciences deal - MarketScreener
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve By Reuters - Investing.com
Edwards Lifesciences Fights FTC Block of JenaValve Deal as EPS Guidance Jumps to $2.55 - Stock Titan
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027 - Benzinga
Edwards Lifesciences Corporation's (NYSE:EW) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance
How volatile is Edwards Lifesciences Corporation stock compared to the marketFree Stock Selection - Jammu Links News
Is Edwards Lifesciences Corporation a growth stock or a value stockHigh-octane investment gains - Jammu Links News
What catalysts could drive Edwards Lifesciences Corporation stock higher in 2025Build wealth with professional market analysis - Jammu Links News
Is it the right time to buy Edwards Lifesciences Corporation stockSuperior portfolio returns - Jammu Links News
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):